PropThink: ILMN To Trade Up On Positive Business Trends, Potential 3Q EPS Upside
By David Moskowitz
Notwithstanding the take-out chatter on Illumina (NASDAQ: ILMN), with the potential that Roche (OTC: RHHBY) may take another run at the company for $60 a share (read more in PropThink's previous article), analysts are out with recent commentary that ILMN's business is performing well, which could drive the stock higher. Two broker dealers, Piper Jaffray and Leerink Swan, have each surveyed labs that use sequencing equipment and published on the results Tuesday and today, respectively, with the broad themes indicating that ILMN's HiSeq product line may have stabilized (previously in decline) and new customer upgrades could enable revenues to beat estimates over the next several quarters. Additionally, the MiSeq sequencing line continues to gain traction, and is the preferred system when users seek to order desktop-based sequencers. Both analysts note that 3Q is looking solid, hinting that Consensus revenue and earnings estimates are conservative (3Q Rev. and EPS estimates are $284.4M and $0.39, respectively). Expect ILMN shares to get a lift from optimism on the business, as well as the chance for earnings upside, with the added benefit that a Roche take out bid could surface. Analysts have mixed opinions on whether the Roche interest is real, but given that ILMN continues to posture as a willing seller, and Roche has clearly demonstrated its interest in ILMN in the past, we are believers.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.
You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at http://www.propthink.com/disclaimer.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: PropThink via Thomson Reuters ONE